 <h1>Pipracil Side Effects</h1><p class="drug-subtitle"><b>Generic Name:</b> <i>piperacillin</i></p><ul class="nav-tabs nav-tabs-collapse nav-tabs-pill">
<li><b class="nav-item here">Side Effects</b></li>
<li>Dosage</li>
<li>Professional</li>
<li>Interactions</li>
<li>Pregnancy</li>
<li class="nav-more">
More&lt;svg aria-hidden="true" class="ddc-icon ddc-icon-down" focusable="false" height="16" viewbox="0 0 24 24" width="16" xmlns="http://www.w3.org/2000/svg"&gt;&lt;path d="M18.5 7.94L19.56 9 12 16.56 4.44 9 5.5 7.94l6.5 6.5z"&gt;&lt;/path&gt;&lt;/svg&gt;
</li>
</ul><ul>
<li>Managing Side Effects</li>
</ul><p class="ddc-notification"><b>Note:</b> This document contains side effect information about piperacillin. Some of the dosage forms listed on this page <em>may not</em> apply to the brand name Pipracil.</p><p><i>Applies to piperacillin: injectable powder for injection</i></p><h3>General</h3><p>This drug was generally well tolerated.  Local side effects (after IV or IM injection) were most common.<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Common</b> (1% to 10%): Diarrhea, loose stools</p><p><b>Frequency not reported</b>: Nausea, vomiting, bloody diarrhea, pseudomembranous colitis, Clostridium difficile-associated diarrhea<sup>[Ref]</sup></p><p>The onset of pseudomembranous colitis symptoms has been reported during or after antimicrobial therapy.<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Common</b> (1% to 10%): Rash, pruritus</p><p><b>Frequency not reported</b>: Vesicular eruptions/vesiculation, erythema multiforme, urticaria, toxic epidermal necrolysis, Stevens-Johnson syndrome, drug reactions with eosinophilia and systemic symptoms (DRESS), petechial rash/purpura, exanthematous pustulosis, bullous dermatosis, erythema nodosum, exanthems, exfoliative dermatitis, Jarisch-Herxheimer reaction<sup>[Ref]</sup></p><p>An increased incidence of rash has been reported in cystic fibrosis patients.</p><p></p><p>DRESS has been reported, particularly with piperacillin-tazobactam.</p><p></p><p>Petechial rash or purpura due to thrombocytopenia has been reported.<sup>[Ref]</sup></p><h3>Local</h3><p><b>Common</b> (1% to 10%): Thrombophlebitis, injection site pain, injection site induration, injection site erythema</p><p><b>Frequency not reported</b>: Ecchymosis, deep vein thrombosis, hematomas<sup>[Ref]</sup></p><p>Thrombophlebitis was more likely when insufficiently diluted solution was injected into the vein.<sup>[Ref]</sup></p><h3>Other</h3><p><b>Common</b> (1% to 10%): Drug fever</p><p><b>Frequency not reported</b>: Fever, edema, fatigue, decreased serum potassium levels, superinfection (including candidiasis), hemorrhagic manifestations<sup>[Ref]</sup></p><p>An increased incidence of fever has been reported in cystic fibrosis patients.</p><p></p><p>Patients with liver disease or those receiving cytotoxic therapy or diuretics have reported decreased serum potassium levels with high doses of this drug.<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Anaphylactic/anaphylactoid reactions (some leading to shock and fatalities)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Frequency not reported</b>: Agranulocytosis, hemolytic anemia, leukopenia, neutropenia, pancytopenia, thrombocytopenia, eosinophilia, bleeding disorders, positive Coombs tests, hemorrhage/bleeding, decreased prothrombin time, platelet dysfunction, prolonged bleeding times<sup>[Ref]</sup></p><p>Risk factors for reversible leukopenia (neutropenia) included prolonged therapy with high doses or concomitant drugs that cause this effect.<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Frequency not reported</b>: Headache, dizziness, seizures/convulsions, prolonged muscle relaxation, paralysis, neurotoxicity, encephalopathy, neuromuscular excitability<sup>[Ref]</sup></p><p>Neuromuscular excitability and convulsions have been reported when higher than recommended doses were given IV.<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Frequency not reported</b>: Elevated serum creatinine, elevated BUN, interstitial nephritis, renal failure<sup>[Ref]</sup></p><p>Drug-induced interstitial nephritis is a rare but potentially serious side effect of all penicillins.<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Frequency not reported</b>: Elevated liver enzymes (LDH, AST, ALT), hyperbilirubinemia, hepatotoxicity, cholestatic hepatitis<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Frequency not reported</b>: Hypokalemia, electrolyte disturbances, acid-base disturbances<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Frequency not reported</b>: Epistaxis</p><p id="ref_1">1. Cerner Multum,   Inc. "Canadian Product Information." O 0 (2015):</p><p id="ref_2">2. Mandell GL "In vitro microbiology and pharmacokinetics of piperacillin." Clin Ther 7 (1985): 37-44</p><p id="ref_3">3. "Product Information. Pipracil (piperacillin)." Lederle Laboratories, Wayne, NJ. </p><p id="ref_4">4. Ramakrishnan K,  Scheid DC "Diagnosis and management of acute pyelonephritis in adults." Am Fam Physician 71 (2005): 933-42</p><p id="ref_5">5. Winston DJ, Murphy W, Young LS, Hewitt WL "Piperacillin therapy for serious bacterial infections." Am J Med 69 (1980): 255-61</p><p id="ref_6">6. Link AS, Jr "Efficacy and safety of ticarcillin plus clavulanic acid and piperacillin in patients with lower respiratory tract infections." Am J Med 79 (1985): 86-7</p><p id="ref_7">7. Eliopoulos GM, Moellering RC "Azlocillin, mezlocillin, and piperacillin: new broad-spectrum penicillins." Ann Intern Med 97 (1982): 755-60</p><p id="ref_8">8. Lutz B, Mogabgab W, Holmes B, et al "Clinical evaluation of the therapeutic efficacy and tolerability of piperacillin." Antimicrob Agents Chemother 22 (1982): 10-4</p><p id="ref_9">9. Abate G,  Godbole K,  Springston C "Piperacillin/tazobactam-induced petechial rash." Ann Pharmacother 44 (2010): 1345-6</p><p id="ref_10">10. Stead RJ, Kennedy HG, Hodson ME, Batten JC "Adverse reactions to piperacillin in cystic fibrosis." Lancet 04/14/84 (1984): 857</p><p id="ref_11">11. Pleasants RA, Walker TR, Samuelson WM "Allergic reactions to parenteral beta-lactam antibiotics in patients with cystic fibrosis." Chest 106 (1994): 1124-8</p><p id="ref_12">12. Strandvik B "Adverse reactions to piperacillin in patients with cystic fibrosis." Lancet 06/16/84 (1984): 1362</p><p id="ref_13">13. Cabanas R, Munoz L, LopezSerrano C, Contreras J, Padial A, Caballero T, MorenoAncillo A, Barranco P "Hypersensitivity to piperacillin." Allergy 53 (1998): 819-20</p><p id="ref_14">14. Moore M, McNamara TR, Johnson J "Elevated bleeding time and epistaxis associated with piperacillin therapy." South Med J 78 (1985): 363</p><p id="ref_15">15. Singh N, Yu VL, Mieles LA, Wagener MM "Beta-lactam antibiotic-induced leukopenia in severe hepatic dysfunction: risk factors and implications for dosing in patients with liver disease." Am J Med 94 (1993): 251-6</p><p id="ref_16">16. Gentry LO, Jemsek JG, Natelson EA "Effects of sodium piperacillin on platelet function in normal volunteers." Antimicrob Agents Chemother 19 (1981): 532-3</p><p id="ref_17">17. Yan MT,  Chu HY,  Chau T,  Lin SH "Profound thrombocytopenia associated with piperacillin in a hemodialysis patient." Clin Nephrol 72 (2009): 240-3</p><p id="ref_18">18. Kirkwood CF, Lasezkay GM "Neutropenia associated with mezlocillin and piperacillin." Drug Intell Clin Pharm 19 (1985): 112-4</p><p id="ref_19">19. Bressler RB, Huston DP "Piperacillin-induced anemia and leukopenia." South Med J 79 (1986): 255-6</p><p id="ref_20">20. Fass RJ, Copelan EA, Brandt JT, Moeschberger ML, Ashton JJ "Platelet-mediated bleeding caused by broad-spectrum penicillins." J Infect Dis 155 (1987): 1242-8</p><p id="ref_21">21. Lee M, Stobnicki M, Sharifi R "Hemorrhagic complications of piperacillin therapy." J Urol 136 (1986): 454-5</p><p id="ref_22">22. Parkmatsumoto YC, Tazawa T "Piperacillin-induced encephalopathy." J Neurol Sci 140 (1996): 141-2</p><p id="ref_23">23. Malanga CJ, Kokontis L, Mauzy S "Piperacillin-induced seizures." Clin Pediatr (Phila) 36 (1997): 475-6</p><p id="ref_24">24. Mackie K, Pavlin EG "Recurrent paralysis following piperacillin administration." Anesthesiology 72 (1990): 561-3</p><h2>More about Pipracil (piperacillin)</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>Drug class: antipseudomonal penicillins</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Bone infection</li>
<li>Cesarean Section</li>
<li>Febrile Neutropenia</li>
<li>Gonococcal Infection, Uncomplicated</li>
<li data-more-config-id="list-data-resources-conditions">... +14 more</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>